U.S. Medicine Shortages Persist as Systemic Issues Continue
Topic: generalRegion: globalUpdated: i3 outletsSources: 4⚠ Bias gap — sources divergeSpectrum: Mostly Center⏱ 4 min read⚠ 3d+ old
Story Summary
SITUATION
The shortage of many medicines in the U.S. remains a systemic problem, with the average drug shortage lasting 5.3 years.
Coveragetap to expand ▾Spectrum: Mostly Center🌍US: 1 · ME: 1 · LatAm: 1 · Other: 1
Political Spectrum
Position is inferred from coverage mix.
i3 outlets · Center
Left
Center
Right
Left: 0
Center: 3
Right: 1
Geography Coverage
Distribution of where coverage is coming from.
i3 unique outlets · Dominant: US/Canada
KEY FACTS
- Negotiations, US officials told NYT, have moved well beyond deliberations on the opening of the Strait of Hormuz, as diplomats have begun narrowing down on four key issues regarding Iran's nuclear program.
- fell by 23% last year, marking the second consecutive year of declines and the lowest level since 2017, according to a new analysis that otherwise found troubling signs about medicines that are in short supply.
- Moreover, nearly two-thirds of out-of-stock medicines were in short supply for more than three years, and 39% were unavailable for more than five years.
- Meanwhile, the 75 drugs that were in short supply last year spanned 130 therapeutic categories, indicating that shortages affected a wide range of diseases and patient populations, according to the analysis by U.S.
HISTORICAL CONTEXT
The ongoing shortage of medicines in the United States has reached a critical point, with recent analyses highlighting a systemic problem that has persisted for several years. This situation has been exacerbated by a variety of factors, including disruptions caused by the COVID-19 pandemic, which began in late 2019 and led to significant strain on global supply chains.
As healthcare systems grappled with the demands of the pandemic, the production and distribution of many essential medications were severely impacted. In 2020, the U.S. saw a notable increase in the number of drug shortages, as manufacturers struggled to maintain production levels amid lockdowns and workforce reductions.
Brief
The ongoing shortage of medicines in the United States is characterized as a systemic problem, with the average duration of shortages extending to 5.3 years in 2025, a significant increase from 4.3 years in 2024.
Although the total number of prescription drug shortages fell by 23% last year, reaching the lowest level since 2017, the analysis reveals troubling trends regarding the longevity and scope of these shortages.
Nearly two-thirds of the medicines that were out of stock had been in short supply for over three years, and 39% had been unavailable for more than five years, indicating a persistent issue affecting various therapeutic categories.
The 75 drugs identified as being in short supply last year spanned 130 different therapeutic categories, highlighting the widespread impact on patients with diverse health needs. The analysis underscores that while there has been a decline in the number of shortages, the systemic issues within the pharmaceutical supply chain continue to pose significant challenges.
This situation raises concerns about the ability of the healthcare system to meet the needs of patients, particularly as the duration of shortages remains alarmingly high.
Where sources differ
Bias gap0.75 / 2.0
Left- and right-leaning outlets are covering this story differently — in which facts to emphasize, which context to include, and how to frame causes and consequences.
Center (3)
en.tempo.costat_newsnytimes.com
Right-leaning (1)
jerusalem_post+0.75
US-Iran nuclear talks saw progress on key issues before recent strikes - report US-Iran nuclear talks saw progress on key issues before recent strikes - report US-Iran nuclear talk…
Sources
4 of 4 linked articles
US-Iran nuclear talks saw progress on key issues before recent strikes - report
jpost.comJun 10Right
↗
US, Iran Focus on Four Key Nuclear Issues as Talks Near Critical Stage
en.tempo.coJun 10Left
↗
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
statnews.comJun 9Left
↗
U.S. and Iran Zero In on Four Nuclear Issues in Talks
nytimes.comJun 9Left
↗